Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
VKTX 
Viking Therapeutics Inc (VKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: VKTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $93.22
1 Year Target Price $93.22
| 10 | Strong Buy |
| 7 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.31% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.30B USD | Price to earnings Ratio - | 1Y Target Price 93.22 |
Price to earnings Ratio - | 1Y Target Price 93.22 | ||
Volume (30-day avg) 19 | Beta 0.64 | 52 Weeks Range 18.92 - 79.10 | Updated Date 11/1/2025 |
52 Weeks Range 18.92 - 79.10 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Earnings Date
Report Date 2025-10-22 | When After Market | Estimate -0.67 | Actual -0.81 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.48% | Return on Equity (TTM) -29.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2328119512 | Price to Sales(TTM) - |
Enterprise Value 2328119512 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -71.64 | Shares Outstanding 113036344 | Shares Floating 110514503 |
Shares Outstanding 113036344 | Shares Floating 110514503 | ||
Percent Insiders 2.17 | Percent Institutions 67.69 |
Upturn AI SWOT
Viking Therapeutics Inc
Company Overview
History and Background
Viking Therapeutics Inc. was founded in 2014. It is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Core Business Areas
- Metabolic Disorders: Viking focuses on developing therapies for diseases like non-alcoholic steatohepatitis (NASH), obesity, and lipid disorders.
Leadership and Structure
The company is led by Brian Lian, Ph.D., as President and CEO. The organizational structure consists of research and development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- VK2809 (NASH): VK2809 is a selective thyroid hormone receptor beta agonist being developed for the treatment of NASH. It is currently in Phase 2b clinical trials. Competitors include Madrigal Pharmaceuticals (MDGL) and Akero Therapeutics (AKRO).
- VK2735 (Obesity): VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of obesity. It is in Phase 1 clinical trials. Competitors include Eli Lilly (LLY) and Novo Nordisk (NVO).
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth driven by increasing prevalence of metabolic disorders and advancements in drug development. There is high competition in areas like NASH and obesity.
Positioning
Viking is positioning itself as a leader in developing innovative therapies for metabolic and endocrine disorders, focusing on NASH and obesity. Its selective receptor agonists aim to offer improved efficacy and safety profiles.
Total Addressable Market (TAM)
The total addressable market for NASH and obesity therapies is estimated to be in the tens of billions of dollars. Viking is aiming to capture a significant share of this market with its novel drug candidates.
Upturn SWOT Analysis
Strengths
- Promising clinical trial data for VK2809 and VK2735
- Strong intellectual property portfolio
- Experienced management team
- Focus on high-value therapeutic areas
Weaknesses
- Clinical-stage company with no currently marketed products
- High cash burn rate
- Reliance on clinical trial success
- Limited commercialization experience
Opportunities
- Positive clinical trial results leading to FDA approval
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing prevalence of NASH and obesity
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- NVO
- MDGL
- AKRO
Competitive Landscape
Viking faces competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel drug candidates and selective receptor agonist approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of its pipeline programs through clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of VK2809 and VK2735, as well as potential partnerships. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include advancing VK2809 and VK2735 through clinical trials, presenting clinical data at scientific conferences, and securing additional funding.
Summary
Viking Therapeutics is a promising clinical-stage company focused on metabolic disorders, particularly NASH and obesity. Its drug candidates, VK2809 and VK2735, have shown promising early results. However, the company faces risks associated with clinical trial success, competition, and regulatory hurdles. Successful trials and potential partnerships are crucial for its future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viking Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-29 | President, CEO & Director Dr. Brian Lian Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | |
Full time employees 50 | |||
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.